BioNexus Gene Lab vs Exagen
BGLC and XGN side by side, both in health services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How BGLC and XGN compare
Exagen is the larger company, worth 42 times as much as BioNexus Gene Lab ($100M against $2.4M).
Exagen grew revenue faster over the last twelve months (13.7% versus −67.3% for BioNexus Gene Lab).
Exagen keeps more of each dollar of sales as profit, with a net margin of −25.1% compared with −82.4% at BioNexus Gene Lab.
BioNexus Gene Lab scores higher on the StockData Score (8 against 4 for Exagen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | BGLC | XGN |
|---|---|---|
| Size and price | ||
| Market cap | $2.4M | $100M |
| Share price | $0.821 | $4.13 |
| Change, 1 year | −83.0% | −56.9% |
| Change, 5 years | −99.6% | −65.9% |
| Beta (5Y) | 0.87 | 1.18 |
| Employees | 6 | 220 |
| StockData Score | ||
| Total score | 8 (better) | 4 |
| Valuation score | 3 (better) | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.8× (better) | 1.4× |
| P/B | 0.3× (better) | 7.3× |
| FCF yield | −35.4% | −13.0% (better) |
| Fair value | $7.45 | $3.60 |
| Margin of safety | 89.0% (better) | −14.7% |
| Growth | ||
| Revenue growth (TTM) | −67.3% | 13.7% (better) |
| Revenue growth, 5Y average | −8.2% | 9.7% (better) |
| Profitability | ||
| Gross margin | 12.3% | 58.7% (better) |
| Operating margin | −81.8% | −20.1% (better) |
| Net margin | −82.4% | −25.1% (better) |
| FCF margin | −27.3% | −18.0% (better) |
| Return on equity | −33.7% (better) | −114% |
| Return on invested capital | −32.3% (better) | −167% |
| Financial health | ||
| Debt / equity | 0.00 | 1.66 (better) |
| Interest coverage | – | −2.9× |
| Current ratio | 6.08 (better) | 3.46 |
| Altman Z-score | 0.32 (better) | −5.71 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 0.49% | 34.1% |
| Held by insiders | 31.0% | 29.2% |
| Insider net buying, 12 months | – | −$22.9K |
| Short interest, % of float | 0.16% | 4.2% |
Go deeper
- BGLC stock overview
- BGLC income statement
- BGLC valuation and score
- XGN stock overview
- XGN income statement
- XGN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.